Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibroma × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 87 Carcinoma, Renal Cell 63 Neoplasm Metastasis 38 Neoplasms 32 Neuroendocrine Tumors 31 Kidney Neoplasms 24 Recurrence 16 Carcinoma, Non-Small-Cell Lung 16 Tuberous Sclerosis 14 Prostatic Neoplasms 14 Triple Negative Breast Neoplasms 13 Head and Neck Neoplasms 12 Glioblastoma 12 Carcinoma, Hepatocellular 12 Pancreatic Neoplasms 11 Lymphoma, Mantle-Cell 11 Lymphoma 11 Brain Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Hodgkin Disease 10 Colorectal Neoplasms 10 Carcinoma, Neuroendocrine 10 Sarcoma 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Glioma 9 Waldenstrom Macroglobulinemia 8 Lymphoma, Follicular 8 Lung Neoplasms 8 Carcinoid Tumor 8

Interventions

mirdametinib 2 tipifarnib 1 talimogene laherparepvec 1 peginterferon alfa-2b 1 nilotinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Talaporfin 1 Sirolimus 1 Restraint, Physical 1 Ranibizumab 1 Radiosurgery 1 Photochemotherapy 1 Neurofibromin 1 1 Mn-PyC3A 1 Everolimus 1 Elasticity Imaging Techniques 1 Deoxycholic Acid 1 Cryotherapy 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡